LLY

1,058.87

+1.65%↑

JNJ

203.92

+0.27%↑

ABBV

236.16

+2.85%↑

UNH

319.35

+2.41%↑

AZN

91.01

+2.64%↑

LLY

1,058.87

+1.65%↑

JNJ

203.92

+0.27%↑

ABBV

236.16

+2.85%↑

UNH

319.35

+2.41%↑

AZN

91.01

+2.64%↑

LLY

1,058.87

+1.65%↑

JNJ

203.92

+0.27%↑

ABBV

236.16

+2.85%↑

UNH

319.35

+2.41%↑

AZN

91.01

+2.64%↑

LLY

1,058.87

+1.65%↑

JNJ

203.92

+0.27%↑

ABBV

236.16

+2.85%↑

UNH

319.35

+2.41%↑

AZN

91.01

+2.64%↑

LLY

1,058.87

+1.65%↑

JNJ

203.92

+0.27%↑

ABBV

236.16

+2.85%↑

UNH

319.35

+2.41%↑

AZN

91.01

+2.64%↑

Home・Aandelen Lijst・Madrigal Pharmaceuticals Inc

Madrigal Pharmaceuticals Inc

Gesloten

SectorGezondheidszorg

546.92 1

Buy Sell

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

546.14

Max

555.37

Belangrijke statistieken
By Trading Economics
Inkomsten	-72M -114M
Verkoop	74M 287M
EPS	-4.956
Winstmarge	-39.75
Werknemers	528
EBITDA	-75M -114M

Aanbevelingen
By TipRanks
Aanbevelingen	Strong Buy
12 Maanden Prognose	+2.51% upside

Marktinformatie
By TradingEconomics
Marktkapitalisatie	3.4B 13B
Vorige openingsprijs	545.92
Vorige sluitingsprijs	546.92

Technische score

By Trading Central

Vertrouwen

Very Strong Bearish Evidence

263.2 / 277.1 Steun & Weerstand

Madrigal Pharmaceuticals Inc Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

23 nov 2025, 22:23 UTC

Acquisities, Fusies, Overnames

BHP Abandons Bid for Anglo American Following New Talks

23 nov 2025, 22:16 UTC

Acquisities, Fusies, Overnames

Macquarie Proposes $7.5 Billion Takeover of Logistics Operator Qube

23 nov 2025, 22:01 UTC

Acquisities, Fusies, Overnames

Macquarie Proposes $7.5B Takeover of Logistics Operator Qube

23 nov 2025, 19:00 UTC

Winsten

Dell, HP Inc., Alibaba, Zoom, Deere, and More Stocks to Watch This Week -- Barrons.com

23 nov 2025, 00:50 UTC

Winsten

Wall Street Goes on a Wild Ride: 'No One Was Expecting This' -- WSJ

22 nov 2025, 10:30 UTC

Winsten

How Google Finally Leapfrogged Rivals With New Gemini Rollout -- WSJ

22 nov 2025, 10:30 UTC

Acquisities, Fusies, Overnames

Investors Clamor for a Peek Behind the Private Markets Curtain -- WSJ

22 nov 2025, 09:20 UTC

Marktinformatie

Winsten

Tech, Media & Telecom Roundup: Market Talk

21 nov 2025, 22:42 UTC

Marktinformatie

Fitch Raises Cyprus's Outlook to Positive From Stable -- Market Talk

21 nov 2025, 21:50 UTC

Marktinformatie

Winsten

Tech, Media & Telecom Roundup: Market Talk

21 nov 2025, 21:50 UTC

Marktinformatie

Basic Materials Roundup: Market Talk

21 nov 2025, 21:47 UTC

Marktinformatie

Mexico's 3Q GDP Prompts Growth Downgrades -- Market Talk

21 nov 2025, 21:43 UTC

Marktinformatie

U.S. Crude Production Defies Low Prices, Rig Count -- Market Talk

21 nov 2025, 20:18 UTC

Marktinformatie

Oil Futures Fall on U.S. Push for Russia-Ukraine Peace -- Market Talk

21 nov 2025, 20:14 UTC

Marktinformatie

U.S. Natural Gas Gains As Traders Focus on Weather -- Market Talk

21 nov 2025, 19:48 UTC

Marktinformatie

Precious Metals Fall for the Week -- Market Talk

21 nov 2025, 19:44 UTC

Winsten

Deere Earnings, Inflation Data, Black Friday: What to Watch in the Next Week -- WSJ

21 nov 2025, 19:37 UTC

Marktinformatie

Dollar Stalls as Stocks and Bonds Rise -- Market Talk

21 nov 2025, 19:27 UTC

Marktinformatie

Winsten

Global Equities Roundup: Market Talk

21 nov 2025, 19:27 UTC

Marktinformatie

Winsten

Intuit Seen With Underappreciated Credit Karma Momentum -- Market Talk

21 nov 2025, 19:20 UTC

Marktinformatie

European Natural Gas Premium Versus U.S. Shrinks -- Market Talk

21 nov 2025, 18:44 UTC

Marktinformatie

Acquisities, Fusies, Overnames

Palo Alto-Chronosphere Synergies Questioned Despite M&A Record -- Market Talk

21 nov 2025, 18:37 UTC

Marktinformatie

U.S. Oil Rig Count Rises By 2 to 419 -- Market Talk

21 nov 2025, 18:34 UTC

Marktinformatie

Winsten

Intuit Seen Outperforming on Conservative Guidance -- Market Talk

21 nov 2025, 18:28 UTC

Winsten

Veeva Systems Earnings Beat Expectations. Why the Stock Is On Pace for Its Largest Drop Since 2023. -- Barrons.com

21 nov 2025, 18:03 UTC

Marktinformatie

Mexico's Inflation Seen Up Slightly in Early November -- Market Talk

21 nov 2025, 17:24 UTC

Marktinformatie

Global Equities Roundup: Market Talk

21 nov 2025, 17:24 UTC

Marktinformatie

Intuit Seen on Path to Increase Growth -- Market Talk

21 nov 2025, 17:20 UTC

Marktinformatie

Basic Materials Roundup: Market Talk

21 nov 2025, 17:05 UTC

Marktinformatie

Lowe's Getting Boost From Busy Small to Medium Pro Customer -- Market Talk

Peer Vergelijking

Prijswijziging

Madrigal Pharmaceuticals Inc Prognose

Koersdoel

By TipRanks

2.51% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 561.73 USD 2.51%

Hoogste 650 USD

Laagste 445 USD

Gebaseerd op 12 Wall Street-analisten die 12-maands prijsdoelen bieden voor Madrigal Pharmaceuticals Inc - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Strong Buy

12 ratings

Buy

Hold

Sell

Gebaseerd op 12 analisten die aandelenratings hebben gegeven aan Madrigal Pharmaceuticals Inc - Dist in de afgelopen 3 maanden.

Technische score

By Trading Central

263.2 / 277.1Steun & Weerstand

Bearish events outweigh bullish events.

Recent bearish events outweigh bullish events.

The bullish and bearish events are balanced.

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

Over Madrigal Pharmaceuticals Inc

Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment of non-alcoholic steatohepatitis (NASH) in the United States. Its lead product candidate is resmetirom, a liver-directed thyroid hormone receptor beta agonist, which is in Phase 3 clinical trials for treating NASH. The company is headquartered in West Conshohocken, Pennsylvania.